{"id":"capreomycin","rwe":[{"pmid":"41898460","year":"2026","title":"Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients.","finding":"","journal":"International journal of molecular sciences","studyType":"Clinical Study"},{"pmid":"41663044","year":"2026","title":"Global whole-genome-based genomic insights into Mycobacterium tuberculosis: Clonal dominance, sequence-type structure, and antimicrobial resistance-virulence landscapes.","finding":"","journal":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases","studyType":"Clinical Study"},{"pmid":"41563373","year":"2026","title":"Public health challenges of tuberculosis in urban slums: Prevalence and drug resistance in Punjab, Pakistan.","finding":"","journal":"Acta microbiologica et immunologica Hungarica","studyType":"Clinical Study"},{"pmid":"41510050","year":"2025","title":"Estimation of second line anti-tubercular drug susceptibility to Mycobacterium tuberculosis in clinical isolates.","finding":"","journal":"Iranian journal of microbiology","studyType":"Clinical Study"},{"pmid":"41449347","year":"2025","title":"Comparative analysis of drug susceptibility among different Mycobacterium abscessus morphotypes.","finding":"","journal":"BMC microbiology","studyType":"Clinical Study"}],"tags":[{"label":"Antimycobacterial","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"J04AB30","category":"atc"},{"label":"Intramuscular","category":"route"},{"label":"Injection","category":"form"},{"label":"Off-Patent","category":"patent"},{"label":"Generic Available","category":"availability"},{"label":"Mature","category":"status"},{"label":"Acute tuberculosis","category":"indication"},{"label":"Pulmonary tuberculosis","category":"indication"},{"label":"Epic Pharma Llc","category":"company"},{"label":"Approved 1970s","category":"decade"},{"label":"Anti-Bacterial Agents","category":"pharmacology"},{"label":"Anti-Infective Agents","category":"pharmacology"},{"label":"Antibiotics, Antitubercular","category":"pharmacology"},{"label":"Antitubercular Agents","category":"pharmacology"},{"label":"Enzyme Inhibitors","category":"pharmacology"},{"label":"Protein Synthesis Inhibitors","category":"pharmacology"}],"phase":"marketed","safety":{"safetySignals":[{"llr":231.428,"date":"","count":74,"signal":"Electrocardiogram QT prolonged","source":"DrugCentral FAERS","actionTaken":"Reported 74 times (LLR=231)"},{"llr":206.009,"date":"","count":59,"signal":"Drug resistance","source":"DrugCentral FAERS","actionTaken":"Reported 59 times (LLR=206)"},{"llr":76.668,"date":"","count":29,"signal":"Hepatotoxicity","source":"DrugCentral FAERS","actionTaken":"Reported 29 times (LLR=77)"},{"llr":69.628,"date":"","count":18,"signal":"Hepatitis B","source":"DrugCentral FAERS","actionTaken":"Reported 18 times (LLR=70)"},{"llr":69.186,"date":"","count":38,"signal":"Neuropathy peripheral","source":"DrugCentral FAERS","actionTaken":"Reported 38 times (LLR=69)"},{"llr":59.066,"date":"","count":13,"signal":"Optic neuropathy","source":"DrugCentral FAERS","actionTaken":"Reported 13 times (LLR=59)"}],"commonSideEffects":[],"contraindications":["Dehydration","Disease of liver","Disorder of the 8th Cranial Nerve","Hearing loss","Hypokalemia","Kidney disease","Neuromuscular block, function"],"specialPopulations":{"Pregnancy":"Capastat Sulfate has been shown to be teratogenic in rats when given in doses 1/2 times the human dose. There are no adequate and well-controlled studies in pregnant women. Capastat Sulfate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus (see boxed WARNINGS and ANIMAL PHARMACOLOGY).","Geriatric use":"Clinical studies of Capastat Sulfate did not analyze the safety and efficacy of patients aged 65 and over to determine whether they respond differently from younger patients. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function and of concomitant disease or other drug therapy.","Paediatric use":"Safety and effectiveness in pediatric patients have not been established (see boxed WARNINGS).","Hepatic impairment":"decreased hepatic"}},"trials":[],"aliases":[],"company":"Epic Pharma Llc","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=CAPREOMYCIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T06:05:57.287194+00:00"},"aiSummary":{"url":"","method":"ai_extraction","source":"AI Strategic Summary","aiModel":"featherless","rawText":"","confidence":0.9,"sourceType":"ai_extraction","retrievedAt":"2026-04-20T06:06:22.140363+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CAPREOMYCIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T06:06:12.711083+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: 70S ribosome inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:06:13.782955+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL2218913/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T06:06:13.430173+00:00"}},"allNames":"capastat sulfate","offLabel":[],"synonyms":["capreomycin","capastat","capostatin","capreomicin","capromycin","capreomycin sulfate","capreomycine","capreomycine sulfate"],"timeline":[{"date":"1971-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from AKORN to Epic Pharma Llc"},{"date":"1971-06-02","type":"positive","source":"DrugCentral","milestone":"FDA approval (Akorn)"},{"date":"2017-11-27","type":"neutral","source":"FDA Orange Book","milestone":"Generic entry — 1 manufacturer approved"}],"aiSummary":"Capreomycin, marketed by Epic Pharma LLC, is an established treatment for acute tuberculosis, with a key composition patent expiring in 2028. Its mechanism of inhibiting protein synthesis in Mycobacterium tuberculosis provides a targeted approach to combating the disease. The primary risk is competition from off-patent generics such as cycloserine and rifabutin, which may erode market share.","brandName":"Capastat Sulfate","ecosystem":[{"indication":"Acute tuberculosis","otherDrugs":[{"name":"aminosalicylic acid","slug":"aminosalicylic-acid","company":"Consolidated Midland"},{"name":"cycloserine","slug":"cycloserine","company":"Purdue Gmp"},{"name":"ethambutol","slug":"ethambutol","company":"Sti Pharma Llc"},{"name":"ethionamide","slug":"ethionamide","company":"Wyeth Pharms Inc"}],"globalPrevalence":1280000},{"indication":"Pulmonary tuberculosis","otherDrugs":[{"name":"aminosalicylic acid","slug":"aminosalicylic-acid","company":"Consolidated Midland"},{"name":"bedaquiline","slug":"bedaquiline","company":"Janssen Therap"},{"name":"cycloserine","slug":"cycloserine","company":"Purdue Gmp"},{"name":"ethambutol","slug":"ethambutol","company":"Sti Pharma Llc"}],"globalPrevalence":1280000}],"mechanism":{"novelty":"Follow-on","modality":"Small Molecule","drugClass":"Antimycobacterial","explanation":"","oneSentence":"","technicalDetail":"Capreomycin binds to the 50S subunit of the bacterial ribosome, specifically to the 5' end of the 23S rRNA, thereby inhibiting peptide bond formation and protein synthesis in Mycobacterium tuberculosis."},"commercial":{"launchDate":"1971","_launchSource":"DrugCentral (FDA 1971-06-02, AKORN)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3063","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=CAPREOMYCIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=CAPREOMYCIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_enrichedAt":"2026-03-30T09:10:37.290487","_validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:06:22.140458+00:00","fieldsConflicting":2,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"cycloserine","drugSlug":"cycloserine","fdaApproval":"1964-06-29","genericCount":1,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"rifampicin","drugSlug":"rifampicin","fdaApproval":"1971-05-21","relationship":"same-class"},{"drugName":"rifamycin","drugSlug":"rifamycin","fdaApproval":"2018-11-16","patentStatus":"Unknown","relationship":"same-class"},{"drugName":"rifabutin","drugSlug":"rifabutin","fdaApproval":"1992-12-23","genericCount":2,"patentStatus":"Off-patent — generic available","relationship":"same-class"},{"drugName":"rifapentine","drugSlug":"rifapentine","fdaApproval":"1998-06-22","patentStatus":"Unknown","relationship":"same-class"}],"genericName":"capreomycin","indications":{"approved":[{"name":"Acute tuberculosis","source":"DrugCentral","snomedId":25629007,"regulator":"FDA","eligibility":"Susceptibility to capreomycin-susceptible strains of M. tuberculosis","usPrevalence":null,"globalPrevalence":1280000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"},{"name":"Pulmonary tuberculosis","source":"DrugCentral","snomedId":154283005,"regulator":"FDA","eligibility":"Susceptibility to capreomycin-susceptible strains of M. tuberculosis, primary agents (isoniazid, rifampin, ethambutol, aminosalicylic acid, and streptomycin) have been ineffective or cannot be used because of toxicity or the presence of resistant tubercle bacilli","usPrevalence":null,"globalPrevalence":1280000,"prevalenceMethod":"curated","prevalenceSource":"Orphanet (European Medicines Agency 2018[INST])"}],"offLabel":[],"pipeline":[]},"currentOwner":"Epic Pharma Llc","drugCategory":"mature","labelChanges":[],"patentStatus":"Off-patent — no active Orange Book patents","relatedDrugs":[{"drugId":"cycloserine","brandName":"cycloserine","genericName":"cycloserine","approvalYear":"1964","relationship":"same-class"},{"drugId":"rifampicin","brandName":"rifampicin","genericName":"rifampicin","approvalYear":"1971","relationship":"same-class"},{"drugId":"rifamycin","brandName":"rifamycin","genericName":"rifamycin","approvalYear":"2018","relationship":"same-class"},{"drugId":"rifabutin","brandName":"rifabutin","genericName":"rifabutin","approvalYear":"1992","relationship":"same-class"},{"drugId":"rifapentine","brandName":"rifapentine","genericName":"rifapentine","approvalYear":"1998","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT00042289","phase":"","title":"Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2003-06-09","conditions":["HIV Infections"],"enrollment":1578,"completionDate":"2020-09-30"},{"nctId":"NCT03237182","phase":"PHASE4","title":"The Individualized M(X) Drug-resistant TB Treatment Strategy Study","status":"TERMINATED","sponsor":"Centre for the AIDS Programme of Research in South Africa","startDate":"2017-06-14","conditions":["Tuberculosis, Multidrug-Resistant"],"enrollment":205,"completionDate":"2022-12-19"},{"nctId":"NCT00000796","phase":"NA","title":"A Prospective Study of Multidrug Resistance and a Pilot Study of the Safety of and Clinical and Microbiologic Response to Levofloxacin in Combination With Other Antimycobacterial Drugs for Treatment of Multidrug-Resistant Pulmonary Tuberculosis (MDRTB) in HIV-Infected Patients.","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"","conditions":["HIV Infections","Tuberculosis"],"enrollment":525,"completionDate":"1998-10"},{"nctId":"NCT02099240","phase":"EARLY_PHASE1","title":"Patients Response to Early Switch To Oral:Osteomyelitis Study","status":"TERMINATED","sponsor":"Julio Ramirez","startDate":"2014-03-06","conditions":["Osteomyelitis"],"enrollment":11,"completionDate":"2018-11-07"},{"nctId":"NCT03625739","phase":"","title":"Population Pharmacokinetics of Anti-tuberculosis Drugs in Children With Tuberculosis","status":"RECRUITING","sponsor":"Beijing Children's Hospital","startDate":"2018-07-01","conditions":["Tuberculosis"],"enrollment":800,"completionDate":"2026-12-31"},{"nctId":"NCT02496572","phase":"","title":"Effectiveness of a Simplified Short Regimen for Multidrug Resistant Tuberculosis in Uzbekistan","status":"UNKNOWN","sponsor":"Medecins Sans Frontieres, Netherlands","startDate":"2013-09","conditions":["Multidrug Resistant Tuberculosis"],"enrollment":110,"completionDate":"2016-04"},{"nctId":"NCT02169141","phase":"","title":"Pharmacokinetics of Levofloxacin and Capreomycin in Multidrug-Resistant Tuberculosis Patients","status":"COMPLETED","sponsor":"University Medical Center Groningen","startDate":"2012-11","conditions":["Tuberculosis"],"enrollment":20,"completionDate":"2013-11"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"administration":{"route":"Intramuscular","formulation":"Injection","formulations":[{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","productName":"CAPASTAT SULFATE"}]},"_patentsChecked":true,"crossReferences":{"NUI":"N0000178639","MMSL":"4345","NDDF":"002787","UNII":"232HYX66HC","VUID":"4019652","CHEBI":"CHEBI:3371","VANDF":"4017459","INN_ID":"1145","RXNORM":"1987","UMLSCUI":"C0262964","chemblId":"CHEMBL2218913","ChEMBL_ID":"CHEMBL2221250","KEGG_DRUG":"D00135","DRUGBANK_ID":"DB00314","PUBCHEM_CID":"3000502","SNOMEDCT_US":"14170004","SECONDARY_CAS_RN":"1405-37-4","MESH_DESCRIPTOR_UI":"D002207"},"formularyStatus":[],"originalProduct":{"form":"INJECTION, POWDER, FOR SOLUTION","route":"INTRAMUSCULAR","company":"Akorn","brandName":"CAPASTAT SULFATE","isOriginal":true,"marketingStatus":"NDA"},"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"1971-","companyName":"Akorn","relationship":"Original Developer"},{"period":"present","companyName":"Epic Pharma Llc","relationship":"Current Owner"}],"publicationCount":738,"therapeuticAreas":["Infectious Disease"],"atcClassification":{"source":"DrugCentral","atcCode":"J04AB30","allCodes":["J04AB30"]},"biosimilarFilings":[],"originalDeveloper":"Akorn","recentPublications":[{"date":"2026 Mar 12","pmid":"41898460","title":"Real-World Assessment of the Xpert MTB/XDR for Detecting Isoniazid and Second-Line Drug Resistance Among TB Patients.","journal":"International journal of molecular sciences"},{"date":"2026 Apr","pmid":"41663044","title":"Global whole-genome-based genomic insights into Mycobacterium tuberculosis: Clonal dominance, sequence-type structure, and antimicrobial resistance-virulence landscapes.","journal":"Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases"},{"date":"2026 Mar 5","pmid":"41563373","title":"Public health challenges of tuberculosis in urban slums: Prevalence and drug resistance in Punjab, Pakistan.","journal":"Acta microbiologica et immunologica Hungarica"},{"date":"2025 Dec","pmid":"41510050","title":"Estimation of second line anti-tubercular drug susceptibility to Mycobacterium tuberculosis in clinical isolates.","journal":"Iranian journal of microbiology"},{"date":"2025 Dec 26","pmid":"41449347","title":"Comparative analysis of drug susceptibility among different Mycobacterium abscessus morphotypes.","journal":"BMC microbiology"}],"companionDiagnostics":[],"genericManufacturers":2,"_genericFilersChecked":true,"genericManufacturerList":["Hisun Pharm Hangzhou","Pharmobedient"],"status":"approved","companyName":"Epic Pharma Llc","companyId":"epic-pharma-llc","modality":"Recombinant protein","firstApprovalDate":"1971","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":1,"withResults":1},"validation":{"fieldsValidated":1,"lastValidatedAt":"2026-04-20T06:06:22.140458+00:00","fieldsConflicting":2,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}